IMPORTANCE A clearer definition of the role of neurofilament light chain (NFL) as a biomarker in amyotrophic lateral sclerosis (ALS) is needed.
S ubstantial efforts have been made to discover biomarkers in amyotrophic lateral sclerosis (ALS) that could act as reliable indicators for early diagnosis, prognosis, and disease progression. Because neurofilaments are the most important scaffolding proteins of the cytoskeleton of the axon, they have been indicated as possible markers of neuronal injury. Despite neurofilament levels having been extensively recognized as promising biomarkers of neuroaxonal breakdown in miscellaneous conditions, [1] [2] [3] [4] [5] [6] the elevation appears to be more significant in patients with ALS. 1, 2, [7] [8] [9] [10] [11] [12] [13] Amyotrophic lateral sclerosis is a neurodegenerative disorder that affects the upper and lower motor neurons, with a median survival of 3 years after the onset of symptoms. 14 The estimated incidence of ALS in Europe is 2 to 16 per 100 000 person-years. Peak age at onset is 58 to 63 years for sporadic disease. Approximately 5% to 10% of cases are familial. 15 Effective treatments are not currently available. Within ALS, variants of motor neuron disease are described, with distinct clinical presentation and rate of progression. 16 Subtypes of ALS with predominant or exclusive involvement of upper or lower motor neuron are associated with better prognosis.
Patients with ALS may develop cognitive dysfunctions, ranging from impaired frontal executive skills (20%-40% of patients) to definite frontotemporal dementia (FTD) in 5% of cases. 17 Both FTD and ALS belong to the same spectrum of neurodegenerative diseases because they share clinical, histopathologic, and genetic features. [18] [19] [20] Neurofilament levels are higher in patients with FTD compared with those with other dementias. 21 The elevation of neurofilament levels might contribute to the definition of the pathologic continuum of FTD and ALS. Neurofilament accumulation is reported in several neurodegenerative diseases. The precise mechanism by which neurofilaments accumulate is still unclear. A failure of the transport of neurofilaments through axons has been described as an early pathologic event in several transgenic models of ALS. 22 A possible explanation for the disruption of this process is the phosphorylation state, 23 because it may contribute to abnormal neurofilament accumulation. 24 Exposure to glutamate was associated with an increase in phosphorylation of neurofilaments in cell bodies, resulting in their pathologic accumulation. This finding emphasizes the concept of glutamate-induced excitotoxicity in some neurodegenerative diseases. 24 In accordance with that finding, the mutant neurofilament peptide, light polypetide (NFL) gene (OMIM 162280) in which serine 55 is converted to aspartate to mimic permanent phosphorylation leads to abnormal accumulation of neurofilaments in motor neurons once transfected into mammalian cells, 25 and mutations of the tail domain of neurofilament heavy chain (NFH), responsible for the hyperphosphorylation of the lysine-serine-proline motifs, are reported in patients with ALS. 26 The aim of our study was to assess the role of NFL as a diagnostic biomarker in ALS, testing the discriminatory capacity between ALS mimics (motor neuropathies [MNs]), FTD, and controls and among different subtypes of motor neuron disease. Another objective was to verify the prognostic value of cerebrospinal fluid (CSF) NFL in patients with ALS by retrospective analysis of longitudinal assessments and survival in distinctive phenotypes of motor neuron disease.
Methods

Participants and Clinical Characterization
This was a single-center, retrospective, longitudinal study of 176 inpatients who underwent a lumbar puncture at the Department of Neurosciences of the University of Padua, Padova, Italy, from January 1, 2010 Finding In this longitudinal study, neurofilament light chain levels were significantly increased in patients with amyotrophic lateral sclerosis compared with those with frontotemporal dementia, those with motor neuropathies, and controls. Among amyotrophic lateral sclerosis subtypes, higher levels of neurofilament light chain were found in patients with upper motor neuron involvement.
Meaning Neurofilament light chain levels may help discriminate amyotrophic lateral sclerosis from other diseases and different phenotypes of amyotrophic lateral sclerosis; low neurofilament light chain levels in patients with lower motor neuron signs could be prognostic of milder phenotypes of disease.
patients carried a C9orf72 GGGGCC-repeat expansion.
Demographic and clinical characteristics were obtained from medical records and directly from patients and controls and included age, disease duration, phenotype of motor neuron disease, cognitive impairment, overall survival, and disease extension assessed by the ALS Functional Rating ScoreRevised (ALSFRS-R) and the ALS Milano-Torino Staging (MITOS) system. 38 Progression rate (ΔFS) until CSF analysis was calculated as follows: ΔFS = (48 − ALSFRS-R Score at Time of Diagnosis)/Duration From Onset to Diagnosis (Months).
39
Sample Collection and Analysis
Cerebrospinal fluid samples were obtained by lumbar puncture, centrifuged, aliquoted, and stored at −80°C. Standard CSF analysis was performed within 1 hour after sample collection, and findings were unremarkable in all patients. The NFL levels were measured in April 2016. An NFL enzyme-linked immunosorbent assay (UmanDiagnostics AB) was used to quantify NFL. 40 Samples from the ALS, FTD, MNs, and control groups were evenly distributed on each plate and measured in duplicate; only CSF samples of patients with ALS were diluted 1:2. Each plate contained calibrators (0-10 000 pg/mL) and quality controls. The interassay and mean intra-assay coefficients of variance were all below 10%. Linearity of the NFL assay was established (0-50 000 pg/mL). 7 
Statistical Analysis
The NFL concentrations in CSF revealed an extremely leftskewed, nonnormal distribution (Shapiro-Wilk test for normality P < .001). After natural logarithm transformation, data appeared to be normally distributed (Shapiro-Wilk test for normality P = .43) (eFigure 1 in the Supplement). Thus, the log-transformed NFL (log[NFL]) concentration was used for graphical representation of data and analysis of covariance (ANCOVA) models. The NFL levels were compared among the ALS, FTD, MNs, and control groups and among different subtypes of ALS using the Mann-Whitney test. Correlations between log[NFL] and quantitative variables (CSF conservation time, disease duration, ΔFS) were assessed using Pearson correlation coefficient. Influence of age and sex on log[NFL] within each group was tested by ANCOVA. The ANCOVA was used within the ALS group with subtype, age, sex, and disease duration as covariates as well. Among patients with typical ALS, the NFL levels were compared between sporadic and genetic ALS, using the Mann-Whitney test and the t test with log-transformed data.
Survival was analyzed with death or tracheostomy as events, recording time in months from the lumbar puncture. Patients who were alive and had not undergone tracheostomy by the last follow-up were censored. A Cox proportional hazards regression model was devised with the following covariates: log[NFL], ALS subtypes, age at onset, sex, cognitive impairment, and ΔFS. Hazard ratios (HRs) were calculated for each quantitative covariate and each level of categorical covariates (subtype with typical ALS as reference and sex with female sex as reference), with 95% CIs. Reference levels were assigned HRs of 1.0.
Ninety-two patients were divided into 4 groups corresponding to NFL concentration quartiles (2 observations deleted because of missing survival data). These groups were used to calculate median survival within NFL concentration ranges and graphically represent survival data in relation to NFL concentration. Kaplan-Meier curves were also estimated for genetic vs sporadic ALS.
Longitudinal changes in the ALSFRS-R and MITOS score were assessed in repeated-measures ANCOVA models, testing for concurrent effects of the following covariates: time elapsed from baseline (0, 6, 12, 24, and 30 months), log[NFL] concentration, age at onset, ALS subtype, sex, cognitive impairment, and ΔFS.
Receiver operating characteristic (ROC) curves were used for a sensitivity analysis of NFL cutoff values for ALS vs all other samples, ALS vs controls, and ALS vs mimics (MNs and FTD). Overall sensitivity and specificity were assessed as areas under the curve (AUCs). We selected optimal cutoff values corresponding to the point in the ROC curve nearest to the upper-left corner of the plot (least sum of the squares of 1 -sensitivity and 1 -specificity).
R version 3.3.0 (R Foundation for Statistical Computing) was used for analyses. The pROC package was used for sensitivity analysis. 41 Statistical significance was set at 2-sided P < .05.
Results
The Table 1 . The CSF conservation time was similar in the 4 groups, whereas a significant difference was found in sex and age distribution, which was accounted for in the ANCOVA models, as mentioned below. The ALS group characteristics are given in the eTable in the Supplement. The NFL concentrations were higher in the ALS (median, 5741.51 pg/mL; interquartile range [IQR], 2494.26-11 911.51 pg/ mL) and FTD groups (median, 2297.50 pg/mL; IQR, 1529.75-3184.97 pg/mL) compared with the MNs (median, 1009.72 pg/mL; IQR, 596.78-1360.81 pg/mL) and control groups (median, 395.53 pg/mL; IQR, 320.44-804.84 pg/mL). Figure 1A shows the levels of NFL in the ALS, FTD, MNs, and control groups after natural logarithm transformation. Sex did not influence NFL levels in the ALS group.
The ANCOVA did not reveal significant effects of sex and age on NFL concentration. The ANCOVA was repeated within the ALS groups to investigate the effect of age, ALS subtype, (F = 15.10, P < .001), and sex (F = 8.81, P = .003), whereas cognitive impairment had no significant effect. In correspondence with these findings, the disease progression assessed by the MITOS score was significantly influenced by log[NFL] level (F = 52.40, P < .001) (Figure 3) . Effects of subtype, age at onset (F = 14.10, P < .001), ΔFS score (F =7 .27 ,P = .007), and sex (F = 4.48, P = .04) were also significant but not that of cognitive impairment.
In An NFL cutoff of 1843.52 pg/mL provided the optimal discrimination between patients with ALS and all other patients at a sensitivity of 81.9% (95% CI, 74.5%-89.4%) and a specificity of 80.5% (95% CI, 71.9%-89%), with an AUC of 0.91 (95% CI, 0.87-0.95). A lower cutoff of 1380.48 pg/mL was most appropriate for differentiation between patients with ALS and controls at a sensitivity of 88.7% (95% CI, 79.5%-97.7%) and a specificity of 89.4% (95% CI, 83%-96%), with an AUC of 0.96 (95% CI, 0.92-0.99). Conversely, a higher cutoff of 3113.03 
Discussion
Our data confirm the role of NFL as a biomarker in ALS, supportive of diagnosis and prognosis. Consistent with previous observations, the NFL concentration was stable over time 6, 9, 12 and independent of age. 8 The NFL levels were considerably higher in the ALS group compared with the FTD, MNs, and control groups ( Figure 1A ). We observed that elevation in NFL concentration in patients with ALS significantly correlates with median survival, even after adjustment for sex, age, ALS subtype, disease duration, and cognitive impairment. The detection of high CSF NFL levels in the early stages of disease would therefore be prognostic of severe progression and worse outcome. We noticed an inverse correlation between the levels of NFL and the time from onset of disease (eFigure 3 in the Supplement). One could object that NFL concentrations are not stable during the disease course and that this finding could be the result of a decrease in NFL levels over time. Investigators 9,11 previously performed serial measurements of phosphorylated NFH and NFH in serum samples from patients with ALS and registered a decrease in values in the later stage of disease, when few motor neurons remain to degenerate. On the other hand, a steady blood expression of NFL over time was reported by Lu et al. 10 Because NFL levels are higher in patients with more severe disease, we believe that those patients with faster progression seek medical attention earlier and exhibit higher values of NFL. In addition, patients with high values of ΔFS, which reflect the disease progression rate from onset to baseline, 39 also presented with higher levels of NFL (eFigure 4 in the Supplement). Additional longitudinal studies with serial measurements of NFL levels are needed to untie this knot. Although executive impairment has been linked to worse prognosis in ALS, 42 we did not find a significant correlation between NFL levels and cognitive dysfunction, which is consistent with previous findings. 13 This discordance may be attributable to the small number of patients. Of interest, our results indicate that NFL levels tend to be higher in subtypes of motor neuron disease with upper motor neuron involvement (ie, typical ALS, PMA, and PBP) compared with those that primarily affect the lower motor neuron (ie, PMA, flail arm syndrome, and flail leg syndrome) ( Figure 1B ). These data are consistent with previous observations 19, 43 in NFL concentration and the corticospinal tract degeneration captured by neuroimaging. The motor neurons that constitute the corticospinal tract are believed to be rich in neurofilament; thus, their damage would result in the release of a high amount of NFL in the CSF. Of note, we found that NFL levels are significantly higher in patients with FTD compared with those with MNs and controls ( Figure 1A ). The elevation of neurofilament concentrations in patients with FTD has been previously reported and started a debate on the role of neurofilaments in defining the clinical and histopathologic continuum between ALS and FTD. 21 To our knowledge, this is the first study to find a sig- Moreover, ALS and FTD share disease mechanisms of proteostasis, and neurofilament accumulations are reported as hallmarks of neurodegenerative disease. Whether the abnormal accumulation of neurofilaments might contribute to the definition of the pathologic continuum of FTD and ALS needs to be established. It would be interesting to explore whether pathologic accumulation of neurofilaments particularly affects the corticospinal tracts.
The prognostic role of NFL is corroborated by our longitudinal assessments with disability scores. The ALSFRS-R and the MITOS score worsen more rapidly in patients with ALS with high concentrations of NFL at baseline (Figure 3) .
With the exception of a few cases, all our patients were receiving riluzole treatment; thus, we cannot postulate on the effect it might exert on NFL levels during the disease. Mc Combe et al 11 did not find any influence of riluzole on serial measurements of serum phosphorylated NFH levels.
The main discrepancy of our data is the great increase of NFL in patients with UMND ALS, despite the widely proven best prognosis associated with this subtype. 16, 47 As expected, data from our cohort of patients with ALS confirmed a slower progression and disability accumulation in the UMND subtype (eFigure 5 in the Supplement). A possible response to this issue is that NFL may reflect the corticospinal tract breakdown, whereas the combination of upper and lower motor 
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Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis neuron degeneration dictates the prognosis, with a main contribution of the respiratory involvement. We found that NFL concentrations are particularly low in patients with flail arm and flail leg syndrome compared with other subtypes of motor neuron disease. If these data are confirmed in larger cohorts of patients, the effect on prognosis definition will be profound because the detection of low NFL concentrations in patients with lower motor neuron signs, especially when confined to the upper or the lower limbs, would be a strong support to the diagnosis of these milder phenotypes. In addition, we could assume that patients with lower motor neuron involvement and high NFL concentrations have a worse prognosis. This approach would have strong consequences on clinical trial enrollment too because it would allow the selection of homogeneous populations of patients at the early stage of disease with minimal disability and a consistent amount of viable motor neurons. Despite the small number of patients, to our knowledge, this is the first study to analyze NFL levels in different subtypes of motor neuron disease.
On the basis of our data, NFL levels are helpful to discriminate between patients with ALS and controls in the diagnostic assessment. However, the test has a weaker diagnostic capability in differentiating between ALS from MNs and FTD, with a higher probability of overlap and a higher false-positive rate. We therefore believe that NFL might be supportive of diagnosis, which still remains eminently clinical. The discriminatory capacity is more relevant if NFL values greatly exceed the cutoff level.
Blood detection of NFL, although less sensitive and sensible compared with CSF measurement, 10 is obviously minimally invasive and will hugely enlarge the cohorts of eligible patients. Moreover, long-term serial measurements will provide more information about NFL expression over time.
Limitations
The main limitation of our study, beyond its retrospective design, was the small number of patients, especially if divided into different clinical subtypes. In addition to the prevalence of disease, the invasive detection of NFL further decreased the sample size.
Conclusions
As mentioned before, NFL measurement is probably heading to the ALS clinic, 48 and our data strongly support this perspective. Despite the diagnosis of ALS being primarily based on clinical examination, further evidence of the diagnostic and prognostic role of NFL will have a profound effect on the selection of patients to enroll in clinical trials, strengthened by the potential discriminatory capacity among different subtypes of motor neuron disease. 
